Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs

Hampshire
19 June 2013 16:31



Hertfordshire
19 June 2013 16:30



Berkshire
19 June 2013 16:25


Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Mark Denton
Managing Director
markd@zenopa.com
+44 1494 818 049

Testimonials
I would like to thank Zenopa for assisting me in finding my new role in Neuro Medical Device Sales. My experience was positive with Zenopa from the date I registered to the date I received the offer.
Craig, 2012

Novo Nordisk signs agreement on emissions reduction

2 May 2007 00:00 in Pharmaceutical Company Restructures


Novo Nordisk has announced that as part of the firm's dedication to reducing its energy consumption and carbon emissions, it has signed a partnership agreement with Dong Energy to utilise wind turbines to supply a key part of its electricity in Denmark.

As part of this deal, Novo Nordisk has stated that it will convert energy savings seen at its production sites in Denmark into the purchase of green electricity from a newly-established wind farm at Horns Rev.

The agreement will see the company lower CO2 emissions, with a target of a ten per cent reduction from 2004 levels by 2014, while Novo Nordisk makes a key contribution to the construction of the Horns Rev II wind farm project.

Lars Clausen, executive vice-president of Dong Energy, said: "It is important that we all take the CO2 issue seriously and take active steps to deal with it.

"Therefore this is an extremely important commercial agreement which we hope will serve as an inspiration to many other companies."

He added that energy companies had a vital position in helping to lower carbon emissions through both their own work and by providing assistance to other businesses nationwide to realise their environmental responsibilities.

Earlier this week, Novo Nordisk announced the inauguration of a $200 million (100 million pound) insulin manufacturing facility in Brazil, the firm's largest site outside its native Denmark.

Other news stories from 02/05/2007

Recent news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



             
© Copyright 2013 Zenopa Ltd